Danna L Jennings, MD
Institute for Neurodegenerative Disorders
9
9
4
N/A
0
0
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+2 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (9)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Danna Jennings, MD
Institute for Neurodegenerative Disorders
Shared therapeutic areas:
Worked with same sponsors:
Sabine Hazan, MD
ProgenaBiome
Shared therapeutic areas:
Ken Nedd, M.D.
GAAD Medical Research Institute Inc.
Shared therapeutic areas:
Nieto Luis
Site Coordinator of United Medical Group
Shared therapeutic areas:
Nieto Luis, Master
Site Coordinator of United Medical Group
Shared therapeutic areas:
Robert B Innis, M.D.
National Institute of Mental Health (NIMH)
Shared therapeutic areas:
Michael B Gill
Power Life Sciences Inc.
Shared therapeutic areas:
Eric M Wassermann, M.D.
National Institute of Neurological Disorders and Stroke (NINDS)
Shared therapeutic areas:
Worked with same sponsors:
Rangashetti Srinivasa, MD
M.S. Ramaiah Memoria Hospital, Bangalore
Shared therapeutic areas:
Chandrashekhar Meshram, MD
Brain and Mind Institute, Nagpur
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (9)
Showing 9 of 9 trials
Study of Individuals With Parkinson's Symptoms But in Whom There is Diagnostic Uncertainty
Assess 123-I IMPY and SPECT Imaging as a Tool to Detect β-Amyloid in the Brain
Evaluation of [123I] MNI-308 and SPECT as a Marker of Beta-amyloid Protein Deposition in AD Subjects Compared to HC
Evaluation of [123I] AV51 and SPECT as a Marker of Beta-amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy Subjects
Development of Cognitive Assessment Tools in Parkinson Disease
Evaluation of [123I] AV151 and SPECT in Subjects w/ AD in Comparison to Healthy Subjects
Evaluation of [123I] AV94 and SPECT in Subjects With Alzheimer Disease in Comparison to Healthy Subjects
Single Photon Emission Computed Tomography (SPECT) Imaging Study to Develop a Biomarker for Alzheimer's Disease
Evaluation of [123I] MNI-340 and SPECT as a Marker of Beta-Amyloid Protein Deposition
All 9 trials loaded